{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":11,"description":"CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22.\n\nRADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16.\n\npaclitaxel: Given IV\n\ncarboplatin: Given IV\n\nexternal beam radiation therapy: Undergo external beam radiation therapy\n\nbrachytherapy: Undergo HDR brachytherapy\n\nintensity-modulated radiation therapy: Undergo IMRT\n\nlaboratory biomarker analysis: Correlative studies","id":"EG000","otherNumAffected":2,"otherNumAtRisk":11,"seriousNumAffected":0,"seriousNumAtRisk":11,"title":"Treatment (Paclitaxel, Carboplatin, Radiotherapy)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Both Grade 1 events","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":2}],"term":"Hypokalemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Hypomagnesemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 2","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Urinary Tract Infection"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Acute Kidney Injury"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Anemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Verbatim term Neutropenia. Grade 1","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Febrile Neutropenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 2","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Alopecia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Peripheral Sensory Neuropathy"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Papulopustular Rash"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Thrombocytopenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 2","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":2}],"term":"Leukopenia"}],"timeFrame":"Every 3 months for the first 2 years and every 6 months for the next 3 years. Up to 5 years total as described in Section 7.4 of the Study Protocol."}